Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Colorectal-cancer-screening update; status in Austria and European countries; and quality assurance of screening-colonoscopy]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	lisdexamfetamine dimesylate (Elvanse®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Recommendations for the use of troponin assays for rapid diagnosis of acute coronary syndrome in the emergency department
2013	National Institute for Health and Care Excellence (NICE)	Autologous blood injection for plantar fasciitis. NICE interventional procedures guidance 437
2013	National Institute for Health and Care Excellence (NICE)	Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. NICE diagnostics guidance 8
2013	NIHR Health Technology Assessment programme	A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE)
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Spectropath Image-Guided Surgery System with Spectropen™ for cancer surgery
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Pazopanib (Votrient®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cataract surgery performed in settings other than hospital operating rooms: clinical effectiveness, cost-effectiveness, and guidelines
2013	Technology Assessment at SickKids (TASK)	Thiopurine dosing using thiopurine methyltransferase status: a systematic review of clinical guidance
2013	National Institute for Health and Care Excellence (NICE)	Autologous blood injection for tendinopathy. NICE interventional procedures guidance 438
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Neochord DS1000™ system for mitral valve regurgitation
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	5-aminolaevulinic acid (Ameluz®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fecal bacteriotherapy for patients with recurrent C. difficile: clinical effectiveness and guidelines
2013	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Economic evaluation of drug eluting stents in the treatment of ischemic heart disease (update)]
2013	National Institute for Health and Care Excellence (NICE)	Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy. NICE interventional procedures guidance 439
2013	NIHR Health Technology Assessment programme	Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study
2013	NIHR Health Technology Assessment programme	Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Eliglustat for gaucher disease
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Techniques for the management of temporary epicardial pacemaker leads: clinical evidence, safety, and guidelines
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	[Relationships between intake of alcoholic beverages and the risk of cardiovascular disease]
2013	Malaysian Health Technology Assessment (MaHTAS)	Epidermal Growth Factor Receptor (EGFR) mutation test for patients with Non-Small Cell Lung Cancer (NSCLC)
2013	NIHR Health Technology Assessment programme	Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive candida infection: the Fungal Infection Risk Evaluation (FIRE) study
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Aflibercept (Eylea) for visual impairment due to diabetic macular oedema – first line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Raltegravir (Isentress®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	[Effect of single room vs contact isolation containment rooms]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Marketing authorisations under exceptional circumstances for oncology drugs: an analysis of approval and reimbursement decisions of four drugs
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Inflectra (infliximab biosimilar) for ankylosing spondylitis
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tegafur/gimeracil/oteracil (Teysuno®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence
2013	Agency for Healthcare Research and Quality (AHRQ)	Communication and dissemination strategies to facilitate the use of health-related evidence
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	[Discharging patients with chronic disease: effect of various forms of cooperation between hospital and the community health service]
2013	Malaysian Health Technology Assessment (MaHTAS)	Colostrum for cosmetic purpose and cell regeneration
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Inflectra (infliximab biosimilar) for psoriatic arthritis
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Botulinum toxin type A (Botox®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Probiotics in infants: clinical effectiveness, safety and guidelines
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	Obstetric consequences of female genital mutilation/cutting (FGM/C)
2013	Malaysian Health Technology Assessment (MaHTAS)	Chlorthalidone for hypertensive patients
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Odanacatib for male osteoporosis – first and second line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etanercept (Enbrel®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety
2013	Norwegian Knowledge Centre for the Health Services (NOKC)	[Effects of interventions for reducing emergency admissions from nursing homes]
2013	Malaysian Health Technology Assessment (MaHTAS)	Avemar granulate as dietary food / special purpose food for cancer
2013	NIHR Horizon Scanning Centre (NIHR HSC)	NeuroAD™ for mild and moderate Alzheimer's Disease
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Saxagliptin (Onglyza®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Patient lifts and transfer equipment for preventing pressure ulcers: a review of clinical and cost-effectiveness and guidelines
2013	Malaysian Health Technology Assessment (MaHTAS)	Water birth
2013	New Zealand National Health Committee (NHC)	Renal denervation – technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Bucelipase-alfa (Kiobrina) for pre-term infants
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lixisenatide (Lyxumia®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Esophageal doppler ultrasound-based cardiac output monitoring for adults undergoing surgery: a review of clinical and cost-effectiveness
2013	New Zealand National Health Committee (NHC)	Percutaneous interventions for mitral regurgitation - technology Note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	ICES13 for stress urinary incontinence in women - second line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sodium phenylbutyrate (Pheburane®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Blood glucose monitors and test strips: a review of the comparative clinical evidence and cost-effectiveness — an update
2013	New Zealand National Health Committee (NHC)	Left atrial appendage – technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Eculizumab (Soliris) for Shiga-Toxin producing Escherichia coli Haemolytic-Uraemic Syndrome – first line
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Etravirine (Intelence®)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Drug therapies for immunosuppression in adult patients following islet cell transplantation for the treatment of diabetes: clinical and cost-effectiveness
2013	New Zealand National Health Committee (NHC)	New and emerging cardiac technologies in Australian and New Zealand public health service over the next decade
2013	NIHR Horizon Scanning Centre (NIHR HSC)	NephroCheck® Test for assessing risk of acute kidney injury
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy and safety of ventricular assist devices]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	JC virus antibody testing for patients with MS: a review of the diagnostic accuracy and guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Treatment by clinical psychologists; Literature overview on training, methods of treatment and areas of application]
2013	Malaysian Health Technology Assessment (MaHTAS)	Transcranial Doppler (TCD) ultrasound and cerebral computed tomography perfusion (CTP) for aneurysmal subarachnoid haemorrhage (SAH)
2013	New Zealand National Health Committee (NHC)	Ventilation tubes: an opportunity for better targeting - technology note
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Nintedanib for idiopathic pulmonary fibrosis – first line
2013	Andalusian Health Technology Assessment Area (AETSA)	[A review of indications for ventricular assist device therapy]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of patients with multiple sclerosis: a review of guidelines
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Hadron therapy: proton and carbon ion therapy - a review of clinical evidence of efficacy, ongoing research and reimbursement]
2013	NIHR Public Health Research (PHR) programme	Systematic review of the effects of schools and school environment interventions on health: evidence mapping and synthesis
2013	NIHR Health Technology Assessment programme	Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ustekinumab (Stelara) for plaque psoriasis in adolescents
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults: safety and guidelines
2013	NIHR Public Health Research (PHR) programme	Systematic review of the effects of schools and school environment interventions on health: evidence mapping and synthesis
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents
2013	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Music therapy in palliative setting]
2013	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy, safety and efficiency of electrical spinal cord stimulation for the treatment of chronic musculoskeletal pain]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Techniques to improve the use of diagnostic laboratory test ordering: clinical evidence
2013	NIHR Public Health Research (PHR) programme	Reducing alcohol-related harm in disadvantaged men: development and feasibility assessment of a brief intervention delivered by mobile telephone
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Pazopanib (Votrient) for renal cell carcinoma – adjuvant therapy
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antibiotic prophylaxis for patients with cardiac or orthopedic implants undergoing dental procedures: a review of the clinical effectiveness and guidelines
2013	NIHR Public Health Research (PHR) programme	Community engagement to reduce inequalities in health: a systematic review, meta-analysis and economic analysis
2013	NIHR Health Technology Assessment programme	A cluster randomised controlled trial of a manualised cognitive behavioural anger management intervention delivered by supervised lay therapists to people with intellectual disabilities
2013	NIHR Health Technology Assessment programme	A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Cost-effectiveness of human papillomavirus vaccination in South Korea]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ponatinib (Iclusig) for chronic myeloid leukaemia
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Biologic response modifier agents as first-line treatment for patients with rheumatoid arthritis: a review of the clinical efficacy, cost-effectiveness and guidelines
2013	NIHR Health Technology Assessment programme	Adjunctive colposcopy technologies for examination of the uterine cervix - DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Prescription patterns and safety of benzodiazepines in Korea]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ramucirumab monotherapy for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma – after prior chemotherapy
2013	NIHR Health Technology Assessment programme	Pixantrone monotherapy for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bone morphogenetic proteins for use in spinal surgery and long bone trauma surgery: a review of the clinical effectiveness and safety
2013	NIHR Health Technology Assessment programme	Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Carfilzomib for relapsed and/or refractory multiple myeloma